Joo Yeon Nam1, Andrea Gilbert2, David Cachia3, Jacob Mandel4, Gregory N Fuller5, Marta Penas-Prado6, John de Groot7, Carlos Kamiya-Matsuoka7. 1. Department of Neuro-Oncology, Rush University Medical Center, Chicago, Illinois. 2. Department of Pathology, Houston Methodist Hospital, Houston, Texas. 3. Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina. 4. Department of Neurology, Baylor College of Medicine, Houston, Texas. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Neuro-Oncology, National Cancer Institute/National Institutes of Health, Bethesda, Maryland. 7. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Pineal parenchymal tumors are exceedingly rare brain tumors responsible for less than 1% of all adult primary intracranial malignancies in the United States. In this study, we describe the clinicopathologic features, management, and outcomes of patients with pineal parenchymal tumor of intermediate differentiation (PPTID). METHODS: We describe a single-center, multidisciplinary team experience in managing PPTID patients over a 15-year period (January 2000 to January 2015) at The University of Texas MD Anderson Cancer Center (MDACC). Pathology was reviewed by the pathology collaborators (A.G. and G.N.F.) and retrospective chart review was performed for treatment and clinical outcomes. RESULTS: We identified 17 patients (9 male) with diagnosis of PPTID. Median age at diagnosis of PPTID was 37 years (range, 15-57 years). Follow-up ranged from 0.1 to 162.8 months with 6 reported deaths. Most patients presented with headaches and diplopia. Three patients had neuroaxial dissemination at initial diagnosis, and recurrence of tumor was common (7/16) despite treatment. CONCLUSIONS: No clear prognostic factors were identified in this series. Extension of resection showed a trend toward improved survival. PPTID with neuroaxial dissemination benefits from aggressive initial treatment including craniospinal irradiation and adjuvant chemotherapy, whereas localized disease may be treated traditionally with maximum debulking followed by adjuvant radiotherapy alone. Long-term monitoring is recommended for neurotoxicity and/or late recurrence.
BACKGROUND: Pineal parenchymal tumors are exceedingly rare brain tumors responsible for less than 1% of all adult primary intracranial malignancies in the United States. In this study, we describe the clinicopathologic features, management, and outcomes of patients with pineal parenchymal tumor of intermediate differentiation (PPTID). METHODS: We describe a single-center, multidisciplinary team experience in managing PPTID patients over a 15-year period (January 2000 to January 2015) at The University of Texas MD Anderson Cancer Center (MDACC). Pathology was reviewed by the pathology collaborators (A.G. and G.N.F.) and retrospective chart review was performed for treatment and clinical outcomes. RESULTS: We identified 17 patients (9 male) with diagnosis of PPTID. Median age at diagnosis of PPTID was 37 years (range, 15-57 years). Follow-up ranged from 0.1 to 162.8 months with 6 reported deaths. Most patients presented with headaches and diplopia. Three patients had neuroaxial dissemination at initial diagnosis, and recurrence of tumor was common (7/16) despite treatment. CONCLUSIONS: No clear prognostic factors were identified in this series. Extension of resection showed a trend toward improved survival. PPTID with neuroaxial dissemination benefits from aggressive initial treatment including craniospinal irradiation and adjuvant chemotherapy, whereas localized disease may be treated traditionally with maximum debulking followed by adjuvant radiotherapy alone. Long-term monitoring is recommended for neurotoxicity and/or late recurrence.
Authors: Julieann C Lee; Tali Mazor; Richard Lao; Eunice Wan; Alpha B Diallo; Nicholas S Hill; Naina Thangaraj; Katherine Wendelsdorf; David Samuel; Cassie N Kline; Anuradha Banerjee; Kurtis Auguste; Corey Raffel; Nalin Gupta; Mitchel Berger; David R Raleigh; Anny Shai; Joanna J Phillips; Andrew W Bollen; Tarik Tihan; Arie Perry; Joseph Costello; David A Solomon Journal: Acta Neuropathol Date: 2019-03-14 Impact factor: 17.088
Authors: S E Schild; B W Scheithauer; P J Schomberg; C C Hook; P J Kelly; L Frick; J S Robinow; S J Buskirk Journal: Cancer Date: 1993-08-01 Impact factor: 6.860
Authors: David R Raleigh; David A Solomon; Shane A Lloyd; Ann Lazar; Michael A Garcia; Penny K Sneed; Jennifer L Clarke; Michael W McDermott; Mitchel S Berger; Tarik Tihan; Daphne A Haas-Kogan Journal: Neuro Oncol Date: 2016-06-09 Impact factor: 12.300
Authors: Bryan K Li; Alexandre Vasiljevic; Christelle Dufour; Fupan Yao; Ben L B Ho; Mei Lu; Eugene I Hwang; Sridharan Gururangan; Jordan R Hansford; Maryam Fouladi; Sumihito Nobusawa; Annie Laquerriere; Marie-Bernadette Delisle; Jason Fangusaro; Fabien Forest; Helen Toledano; Palma Solano-Paez; Sarah Leary; Diane Birks; Lindsey M Hoffman; Alexandru Szathmari; Cécile Faure-Conter; Xing Fan; Daniel Catchpoole; Li Zhou; Kris Ann P Schultz; Koichi Ichimura; Guillaume Gauchotte; Nada Jabado; Chris Jones; Delphine Loussouarn; Karima Mokhtari; Audrey Rousseau; David S Ziegler; Shinya Tanaka; Scott L Pomeroy; Amar Gajjar; Vijay Ramaswamy; Cynthia Hawkins; Richard G Grundy; D Ashley Hill; Eric Bouffet; Annie Huang; Anne Jouvet Journal: Acta Neuropathol Date: 2019-12-09 Impact factor: 17.088
Authors: Matija Snuderl; Kasthuri Kannan; Elke Pfaff; Shiyang Wang; James M Stafford; Jonathan Serrano; Adriana Heguy; Karina Ray; Arline Faustin; Olga Aminova; Igor Dolgalev; Stacie L Stapleton; David Zagzag; Luis Chiriboga; Sharon L Gardner; Jeffrey H Wisoff; John G Golfinos; David Capper; Volker Hovestadt; Marc K Rosenblum; Dimitris G Placantonakis; Sarah E LeBoeuf; Thales Y Papagiannakopoulos; Lukas Chavez; Sama Ahsan; Charles G Eberhart; Stefan M Pfister; David T W Jones; Matthias A Karajannis Journal: Nat Commun Date: 2018-07-20 Impact factor: 14.919
Authors: Matthew J Shepard; Ali S Haider; Sujit S Prabhu; Raymond Sawaya; Franco DeMonte; Ian E McCutcheon; Jeffrey S Weinberg; Sherise D Ferguson; Dima Suki; Gregory N Fuller; Frederick F Lang Journal: J Neurooncol Date: 2022-01-27 Impact factor: 4.130
Authors: Panagiotis Kerezoudis; Yagiz Ugur Yolcu; Nadia N Laack; Michael W Ruff; Soumen Khatua; David J Daniels; Terry C Burns; Sani H Kizilbash Journal: Neurooncol Adv Date: 2022-04-17